Date: August 11th, 2016
To: All AHS Zones – Laboratory Directors, Managers, Supervisors, Physicians and Allied Health Care Professionals
From: All AHS Laboratory Services, Calgary Laboratory Services and DynaLIFE Dx Diagnostic Laboratory Services
Re: Fetal Fibronectin Result Comment for Discontinuation of Testing

Please post or distribute as widely as appropriate

Key Messages:
- Starting August 16th, 2016, all Fetal Fibronectin (fFN) test results will be reported with the following comment:

Why this is important:
- A post-implementation evaluation completed by the Maternal Newborn Child & Youth Strategic Clinical Network (SCN) of the efficacy of cervical/vaginal fetal fibronectin (fFN) in the evaluation and treatment of threatened preterm labour in Alberta, concluded that fFN did not result in improved preterm labor prediction, management, care, outcome or cost savings.
- Discontinuation of Fetal Fibronectin testing will be implemented in October 2016.

Action Required:
- Review of additional supporting information on management of preterm labour and the Practice Support Guideline- Clinical Assessment of ‘At Risk’ or Actual Preterm Labour for Triage Guideline may be found at: http://insite.albertahealthservices.ca/7363.asp or http://www.albertahealthservices.ca/info/Page7451.aspx

Inquiries and feedback may be directed to:

Dr. Radha Chari at Radha.Chari@ahs.ca
or
Dr. Doug Wilson at Doug.Wison@ahs.ca

This bulletin has been reviewed and approved by:

Dr. Carolyn O’Hara, Interim Medical Director, AHS Laboratory Services